NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Mankind Pharma Credit Ratings Reaffirmed by ICRA for ₹6,250 Crore Debt Instruments
ICRA Limited has reaffirmed the credit ratings for Mankind Pharma's debt instruments totaling ₹6,250 crore. The Non-Convertible Debentures (NCDs) worth ₹5,000 crore maintained an [ICRA]AA+/Stable rating. Additionally, long-term and short-term fund-based limits of ₹1,250 crore were reaffirmed at [ICRA]AA+ (Stable) and [ICRA]A1+ respectively. This reaffirmation reflects the company's strong financial profile and continued creditworthiness in the pharmaceutical sector.
முக்கிய அம்சங்கள்
ICRA reaffirmed [ICRA]AA+/Stable rating for ₹5,000 crore Non-Convertible Debentures.Fund-based limits of ₹1,250 crore reaffirmed at [ICRA]AA+ (Stable) and [ICRA]A1+.Total debt instruments covered under this rating action amount to ₹6,250 crore.The 'Stable' outlook indicates ICRA's expectation of consistent performance and credit metrics.
👀 கவனிக்க வேண்டியவை
The reaffirmation of high credit ratings confirms the company's strong balance sheet and low default risk. Investors should view this as a validation of financial stability, requiring no immediate portfolio changes.
Mankind Pharma Subsidiary BSV Subjected to 6-Day GST Search and Inspection
The GST Department, Mumbai, conducted a search and inspection operation at Bharat Serums and Vaccines Limited (BSV), a wholly owned subsidiary of Mankind Pharma. The operation took place over six days, from February 3 to February 8, 2026, under Section 67 of the Maharashtra GST Act. The inspection focused on tax payments, input tax credit claims, reconciliation, and refunds. Mankind Pharma has officially stated that the search has resulted in no material impact on the subsidiary's financials or operations.
முக்கிய அம்சங்கள்
Search conducted by Assistant Commissioner of State Tax (Investigation – B), MumbaiOperation lasted 6 days from February 3 to February 8, 2026Focus areas included GST tax payments, input tax credit (ITC) reconciliation, and refundsManagement confirms no material impact on BSV's financial or operational activitiesBSV is a wholly owned unlisted subsidiary of Mankind Pharma Limited
👀 கவனிக்க வேண்டியவை
Investors should monitor for any subsequent tax demand notices or penalties that may arise from this inspection. While the company claims no material impact, any future liability could affect the subsidiary's valuation.
Mankind Pharma Q3 FY26 Revenue Up 11.5% to ₹3,567 Cr; Adjusted EBITDA Margin at 25.9%
Mankind Pharma reported a steady Q3 FY26 with revenue growing 11.5% YoY to INR 3,567 crores, driven by an 11.1% increase in domestic sales and 14% growth in exports. The company's adjusted EBITDA margin stood at 25.9%, while the chronic segment's contribution rose to 36.7% of total sales. Integration of the BSV acquisition showed positive results with double-digit growth, and the company successfully reduced its net debt to INR 4,294 crores. Management highlighted a recovery in volume growth and significant outperformance in cardio and anti-diabetic therapies compared to the market.
முக்கிய அம்சங்கள்
Q3 FY26 revenue increased 11.5% YoY to ₹3,567 crores with an adjusted EBITDA margin of 25.9%.Chronic therapy contribution rose to 36.7%, with cardio and anti-diabetes growing at 16.7% and 14.4% respectively.Export revenue for 9M FY26 surged 51% YoY to ₹1,503 crores, supported by EU GMP certification for the Udaipur facility.Net debt reduced to ₹4,294 crores, bringing the net debt to adjusted EBITDA ratio down to 1.3x.Domestic PCPM improved to ₹7.2 lakhs from ₹6.5 lakhs on a trailing 12-month basis.
👀 கவனிக்க வேண்டியவை
Investors should monitor the continued integration of BSV and the recovery in the acute segment. The stock remains a strong play on the domestic chronic market and expanding export capabilities.
Mankind Pharma Q3 FY26 Standalone PAT at ₹449.47 Cr; Revenue at ₹2,632.68 Cr
Mankind Pharma reported a steady performance for Q3 FY26 with standalone revenue from operations at ₹2,632.68 crore, showing a marginal sequential dip from ₹2,636.95 crore in Q2. Standalone Profit After Tax (PAT) stood at ₹449.47 crore, slightly lower than the ₹462.27 crore reported in the previous quarter, partly due to an exceptional item of ₹83.42 crore. The financial results have been restated to account for the acquisition of Bharat Serums and Vaccines Limited (BSV) and other business combinations. Overall, the company maintains a strong balance sheet with a total comprehensive income of ₹452.53 crore for the quarter.
முக்கிய அம்சங்கள்
Standalone Revenue from operations stood at ₹2,632.68 crore for the quarter ended December 31, 2025.Standalone Profit After Tax (PAT) reached ₹449.47 crore, impacted by an exceptional charge of ₹83.42 crore.Basic Earnings Per Share (EPS) for the quarter was reported at ₹10.89.Financials were restated to reflect the impact of the Bharat Serums and Vaccines Limited (BSV) acquisition.Total expenses for the quarter were managed at ₹2,100.49 crore compared to ₹2,189.09 crore in the preceding quarter.
👀 கவனிக்க வேண்டியவை
Investors should monitor the integration progress of the BSV acquisition and the reasons behind the exceptional item. While sequential growth was flat, the company's domestic market leadership remains a key long-term positive.
Mankind Pharma Q3 FY26: Revenue up 11.5% to ₹3,567 Cr; Chronic share rises to 39.3%
Mankind Pharma reported a steady 11.5% YoY revenue growth in Q3 FY26, reaching ₹3,567 crore, primarily driven by domestic pharma and the consolidation of BSV. The company's chronic segment showed strong momentum, with its share increasing by 200bps to 39.3%, led by high growth in Cardiac (16.7%) and Anti-Diabetes (14.4%) therapies. While reported EBITDA margins were 22.9%, adjusted margins stood at 25.9% after accounting for one-time labor code impacts. The Consumer Healthcare segment regained momentum with 5.2% growth, and the export business grew by 14.1% YoY.
முக்கிய அம்சங்கள்
Revenue from operations grew 11.5% YoY to ₹3,567 crore, with domestic business contributing ₹3,046 crore.Chronic segment share increased to 39.3% from 37.3% YoY, significantly outperforming the Indian Pharma Market (IPM) in key therapies.Adjusted EBITDA margin stood at 25.9%, while PAT grew 9.5% YoY to ₹414 crore.Export business witnessed 14.1% YoY growth, reaching ₹521 crore, aided by BSV international business.Net debt reduced to ₹4,294 crore as of Dec 31, 2025, from ₹6,739 crore in Dec 2024, showing strong cash flow utilization.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's successful transition toward a higher-margin chronic portfolio and the smooth integration of the BSV acquisition. The stock remains a strong play on the domestic pharmaceutical market with improving capital efficiency.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Mankind Pharma has announced the withdrawal of its (ICRA) A1+ credit rating for Commercial Paper worth ₹1,500 crore at its own request. Despite this withdrawal, the company's core credit profile remains strong with an outstanding (ICRA) AA+/Stable rating for its ₹5,000 crore Non-Convertible Debentures. Additionally, fund-based limits totaling ₹1,250 crore retain their high-grade (ICRA) AA+ (Stable) and (ICRA) A1+ ratings. This update confirms that the company's creditworthiness and ability to service debt remain robust.
முக்கிய அம்சங்கள்
ICRA withdrew the (ICRA) A1+ rating for ₹1,500 crore Commercial Paper at the company's request.Outstanding rating for ₹5,000 crore Non-Convertible Debentures remains stable at (ICRA) AA+.Long-term and short-term fund-based limits of ₹1,250 crore maintain (ICRA) AA+ (Stable) and (ICRA) A1+ ratings.The withdrawal of the CP rating is a procedural action and does not indicate a downgrade in credit quality.
👀 கவனிக்க வேண்டியவை
Investors should treat this as a routine administrative update as the company's primary credit ratings remain high and stable. No immediate action is required as the fundamental debt-servicing capability remains unchanged.
Mankind Pharma Assigned ESG Rating of 71 by NSE Sustainability
Mankind Pharma Limited has been assigned an Environmental, Social, and Governance (ESG) rating of 71 for FY25 by NSE Sustainability Ratings and Analytics Limited. This rating was assigned independently based on publicly available information, as the company did not specifically engage the provider for this service. The disclosure is in compliance with SEBI's Master Circular for ESG Rating Providers. A score of 71 suggests a robust framework in sustainability and governance, which is a key metric for institutional and foreign investors.
முக்கிய அம்சங்கள்
NSE Sustainability assigned an ESG rating of 71 to Mankind Pharma for the 2025 financial year.The rating was assigned independently using publicly available information without company engagement.The disclosure follows the SEBI Master Circular dated November 11, 2024, regarding ESG Rating Providers.
👀 கவனிக்க வேண்டியவை
Monitor how this rating compares to industry peers to gauge the company's relative sustainability standing. This positive score may enhance the stock's attractiveness to ESG-mandated institutional funds.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
